In Focus For Viva Entertainment Group Inc.

New Post Public Reply Private Reply Replies (0) Message Board
BionicBen
302
In Focus For Viva Entertainment Group Inc. (OTCPK:OTTV)

http://ozarktimes.com/qi-in-focus-for-viva-en...tv/266923/

Viva Entertainment Group Inc. (OTCPK:OTTV) has a Q.i. Value of 50.00000. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield.

Checking in on some valuation rankings, Viva Entertainment Group Inc. (OTCPK:OTTV) has a Value Composite score of 85. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales.

Occasionally, investors may feel like they are riding on a wild roller coaster when dealing with the stock market. Controlling emotions when taking the ride may assist with making necessary decisions when the time comes. Many investors choose to do thorough research when purchasing any stock. Knowing what is owned and why it is owned may help ease the mind when things get sticky. When the market is riding high and there is generally smooth sailing on the investing seas, individual investors may have the tendency to get complacent. Being prepared for any situation may help ease the stress of big market decision making. There may be a time when it seems like everything is going off the rails, but having an actual game plan for management and recovery could make a huge difference both financially and psychologically.

The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 80.

Viva Entertainment Group Inc. (OTCPK:OTTV) has a current ERP5 Rank of 17018. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Looking at some alternate time periods, the 12 month price index is 0.03895, the 24 month is 0.03700, and the 36 month is 0.03700. Narrowing in a bit closer, the 5 month price index is 1.37037, the 3 month is 6.16667, and the 1 month is currently 2.05556.

Watching some historical volatility numbers on shares of Viva Entertainment Group Inc. (OTCPK:OTTV), we can see that the 12 month volatility is presently 309.937500. The 6 month volatility is 387.975100, and the 3 month is spotted at 461.945500.

Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

We can now take a quick look at some historical stock price index data. Viva Entertainment Group Inc. (OTCPK:OTTV) presently has a 10 month price index of 0.18500. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period.

Disclaimer:
There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator.
Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.
There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in all and any posts.
My posts are NOT investment advice. I am not paid to post.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LIV Golf's Big Play: Restructuring with Saudi PIF

Updated Category News Views 6

Trailblazing Change in the Golf World It's like watching a high-stakes game of chess where pieces are worth billions. White Knight Capital Corp. has thrown its hat into the ring with the Public Investment Fund of Saudi Arabia to overhaul LIV Golf Enterprises. This isn't your average Monday morning golf chat; it's full-on corporate drama with financial steroids. Debt Swap...

Continue Reading
Innovative SOV Launches for Offshore Wind Revolution

Updated Category News Views 2

A New Era for Offshore Wind Operations Mark my words, folks, this launch ain't just some minor milestone swaying gently on the industry seas. ZPMC's 'Wind of Ocean' is about to kickstart a whole new game in Europe's offshore wind space. Built with brains and brawn, this vessel embodies the future of sustainable and efficient offshore operations. The announcement from...

Continue Reading
MiniTool MovieMaker 8.9: Keyframe Animation Upgrade

Updated Category News Views 2

Breaking Down MiniTool MovieMaker 8.9's Revamp Kicking off the day with some noteworthy news in the creative software arena, MiniTool's latest update to its MovieMaker program is grabbing attention. It’s not often you hear software developers hitting the right balance between functionality and simplicity as they've done with this release. Keyframe Animation: The Star of...

Continue Reading
Fujifilm's New 400mm Lens: A Game Changer?

Updated Category News Views 1

Big Moves from Fujifilm's Camp Now we're talking, Fujifilm! Just when you think they might ease off the throttle, they crank up the heat with the XF 400mm f/4.5 R LM OIS WR lens. This isn’t just your run-of-the-mill update. It's a significant addition to their already beefed-up lineup for sports and wildlife. You know what that means: more reach, less baggage. Compact...

Continue Reading
Argo Biopharma's BW-20805 Shows Promise in HAE Phase II Trial

Updated Category News Views 1

Argo's Gains in Hereditary Angioedema Therapy Think about it, folks – reducing a hereditary angioedema attack by over 80%? Argo Biopharma, the slick operator in the RNA therapeutics space, is flexing its muscles again. They've hauled in some impressive data for their siRNA therapeutic, BW-20805, at the 2026 Bradykinin Symposium in Berlin. For you deep-pocketed investors...

Continue Reading
Clinical Trials Services Market Set for Big Growth

Updated Category News Views 2

Eyeing a Market Surge in Clinical Trials Numbers don't lie, and they're painting a promising picture for the clinical trials services market with a solid 8% growth forecasted annually till 2031. From a modest $66.20 billion in 2026, we're looking at ballooning to a hefty $97.41 billion by 2031. What’s cooking? Let me dish it out for you. Key Drivers and Dynamics North...

Continue Reading
Potomac Edison Eyes Rate Hike for System Overhaul

Updated Category News Views 0

FirstEnergy's Potomac Edison Pushes for Rate Adjustment The walls are closing in on the energy sector, and Potomac Edison is seizing the moment. With their proposed $52.8 million rate adjustment, they're not only aiming to keep the lights on but to power up their entire infrastructure game. It's a gutsy move, particularly in volatile times. The Price Tag: Weighing Costs...

Continue Reading
Pathlock Faces Identity Governance Opportunities in 2026

Updated Category News Views 3

Challenges in Identity Governance Emerge for 2026 Imagine a world where digital identities run wild—unmonitored, orphaned, dormant. Welcome to 2026, where identity governance and administration (IGA) face a reckoning, dragging enterprises into the spotlight as they scramble to protect against identity chaos. With Pathlock’s recent recognition in the Gartner Market...

Continue Reading
Reolink Unveils OMVI 2i Ultra at IFA 2026

Updated Category News Views 6

Reolink's Bold Move Into the Future of Home Security Amidst the hustle of Berlin's IFA 2026, Reolink dropped its latest gem: the OMVI 2i Ultra—an all-in-one security powerhouse promising to change the game for home protection junkies. As usual, Reolink's got its eyes on the prize, pushing boundaries with this latest lineup. OMVI 2i Ultra: Dual-View Revolution If you've...

Continue Reading
China's Diplomatic Dance: SCO Summit & Key Visits

Updated Category News Views 2

A Diplomatic Balancing Act Xi Jinping's recent diplomatic tour, climaxing at the Shanghai Cooperation Organization (SCO) Summit and extending through critical visits to Kyrgyzstan and Egypt, paints a compelling picture of China's strategic intentions. For those of us watching the geopolitical chessboard, it's like seeing a master strategist at work—pondering a tricky...

Continue Reading

Top 5 Most Recently Viewed Articles

Theravance Buyout Scrutinized: Is Zymeworks Deal Fair?

Updated Category News Views 6

Theravance and Zymeworks: What's the Deal? First things first, the numbers. Theravance Biopharma, the biotech entity waving its NASDAQ: TBPH ticker, is about to jump into bed with Zymeworks, another player in the pharma game. The pitch? One hundred seventy-six bucks a share in cold, hard cash, plus a contingent value right. That's right—sweet on paper, but always worth...

Continue Reading
Top Stock Split Opportunities for Maximum Growth Potential

Updated Category News Views 72

Stock splits surged back into the limelight recently, flipping the script on a strategy that had been gathering dust. Once thought outdated, these moves have become hot again, reflecting how companies with robust performances can maintain investor interest while managing share prices effectively. When you see a stock split, it’s often more than just a number game; it's...

Continue Reading
Roc Nation and Musicow: Pioneering a New Era in Music Equity

Updated Category News Views 455

Roc Nation Collaborates with Musicow for Music Equity Innovation Roc Nation has embarked on an exciting partnership with Musicow, a South Korean fintech firm. This collaboration aims to introduce the first Music Equity Service Provider (MESP) in the United States. By allowing music rights holders to buy, sell, and trade shares in music royalty revenue, this initiative...

Continue Reading
Latest Updates from the FDA: New Guidelines and Approvals

Updated Category News Views 396

Insights from Recent FDA Activities The U.S. Food and Drug Administration (FDA) has released an overview of recent important developments aimed at enhancing public health and safety. These updates offer invaluable information about various health issues, product approvals, and guidance to manufacturers. Investigation of E. coli Outbreak Recently, the FDA updated its...

Continue Reading
Insider Sale Sparks Interest in BorgWarner's Future Prospects

Updated Category News Views 173

Understanding Insider Transactions at BorgWarner Recently, a notable insider sale captured attention. Isabelle McKenzie, the Vice President of BorgWarner, made headlines when she sold 2,500 shares, totaling around $100,025. This transaction was officially reported in a filing to the SEC, particularly through a Form 4. Such insider activities often spark curiosity among...

Continue Reading